We studied the effects of serotonin on compound action potentials in dorsal columns isolated from young (nine to 13 days old) rats. Conducting action potentials were activated by submaximal (50%) and supramaximal constant current electrical stimuli and recorded with glass micropipettes. At 10 μM and 100 μM concentrations, serotonin significantly increased mean action potential amplitudes by9.6 ± 6.5% (± S.D., P <0.05) and16.6 ± 12.2% (± S.D., P < 0.005), respectively. Likewise, 10μM and 100μM of quipazine (a serotonhin 2A agonist) increased the amplitudes by9.6 ± 2.5% (± S.D., P < 0.0005) and37.7 ± 8.7% (± S.D., P < 0.0005), respectively. In contrast, 10 μM and 100 μM concentrations of 8-hydroxy-dipropylaminotetralin-hydrobromide (a serotonin 1A agonist) reduced axonal excitability by−9.4 ± 5.5% (±S.D., P <0.05) and−32.9 ± 10.6% (±S.D., P < 0.0005), respectively. At 50 μM concentration, mianserin (a serotonin 2A and serotonin 2C antagonist) eliminated the excitatory effects of 100 μM quipazine dimaleate. The combination of 50 μM mianserin and 100 μM serotonin reduced action potential amplitudes by−5.6 ± 4.9% (±S.D., P < 0.05). These results suggest that serotonin 1A and serotonin 2A receptor subtypes are present on spinal dorsal column axons. These two receptor subtypes have opposing effects on axonal excitability. The ratios and sensitivies of these two axonal receptor subtypes may modulate axonal excitability in rat dorsal column axons and have important implications for both development and injury of axons.
Read full abstract